An effective assessment of simvastatin-induced toxicity with NMR-based metabonomics approach

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Yang, Hye ji ^a   Choi, Myung Joo ^a   Wen, He ^a   Kwon, Hyuk Nam ^a   Jung, Kyung Hee ^a   Hong, Sang Won ^a   Kim, Joon Mee ^a   Hong, Soon Sun ^a   Park, Sunghyouk ^a  

^a Inha University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; SIMVASTATIN; ANTILIPEMIC AGENT; PHARMACOLOGICAL BIOMARKER;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOMICS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; ENZYME ANALYSIS; FEMALE; HISTOPATHOLOGY; LIVER PARENCHYMA; LIVER TOXICITY; METABONOMICS; NON INVASIVE PROCEDURE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; RELIABILITY; TOXICITY TESTING; TREATMENT DURATION; URINALYSIS; URINE LEVEL; ANIMAL; BLOOD; BLOOD ANALYSIS; DRUG EFFECT; DRUG SCREENING; DRUG TOXICITY; INSTRUMENTATION; LIVER; METABOLISM; METABOLOME; METABOLOMICS; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE; PATHOLOGY; TREATMENT OUTCOME; URINE; VALIDATION STUDY; WISTAR RAT;

ANIMALS; BIOMARKERS, PHARMACOLOGICAL; BLOOD CHEMICAL ANALYSIS; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; FEMALE; HYPOLIPIDEMIC AGENTS; LIVER; METABOLOME; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; RATS; RATS, WISTAR; SIMVASTATIN; TREATMENT OUTCOME; URINALYSIS;

EID: 79952051904     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016641     Document Type: Article

References (38)

1. Collins R, Armitage J, Parish S, Sleigh P, Peto R, (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005-2016.
2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-1009.
3. Henke AC, Jensen CS, Cohen MB, (2002) Cytologic diagnosis of adenocarcinoma in biliary and pancreatic duct brushings. Adv Anat Pathol 9: 301-308.
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301-1307.
5. Corsini A, Bernini F, Quarato P, Donetti E, Bellosta S, et al. (1996) Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology 87: 458-468.
6. Olsson AG, (2009) [The last round about statins: there is the fact that 80 mg simvastatin daily results in high risk of myopathy]. Lakartidningen 106: 2783-2784; author reply 2784.
7. Parker N, (1991) The Garry David case. Aust N Z J Psychiatry 25: 371-374.
8. Farmer JA, Torre-Amione G, (2000) Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf 23: 197-213.
9. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, et al. (2002) ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40: 567-572.
10. Rosenson RS, (2004) Current overview of statin-induced myopathy. Am J Med 116: 408-416.
11. Davidson MH, (2002) Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 90: 50K-60K.
12. Clarke AT, Mills PR, (2006) Atorvastatin associated liver disease. Dig Liver Dis 38: 772-777.
13. Nicholson JK, Lindon JC, Holmes E, (1999) 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29: 1181-1189.
14. Nicholson JK, Connelly J, Lindon JC, Holmes E, (2002) Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 1: 153-161.
15. Reo NV, (2002) NMR-based metabolomics. Drug Chem Toxicol 25: 375-382.
16. Borgert CJ, (2007) Predicting interactions from mechanistic information: can omic data validate theories? Toxicol Appl Pharmacol 223: 114-120.
17. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, et al. (2006) Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440: 1073-1077.
18. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK, (2009) Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A 106: 14728-14733.
19. Mortishire-Smith RJ, Skiles GL, Lawrence JW, Spence S, Nicholls AW, et al. (2004) Use of metabonomics to identify impaired fatty acid metabolism as the mechanism of a drug-induced toxicity. Chem Res Toxicol 17: 165-173.
20. Schnackenberg LK, Beger RD, (2008) The role of metabolic biomarkers in drug toxicity studies. Toxicol Mech Methods 18: 301-311.
21. Bollard ME, Keun HC, Beckonert O, Ebbels TM, Antti H, et al. (2005) Comparative metabonomics of differential hydrazine toxicity in the rat and mouse. Toxicol Appl Pharmacol 204: 135-151.
22. Coen M, Holmes E, Lindon JC, Nicholson JK, (2008) NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem Res Toxicol 21: 9-27.
23. Idborg H, Zamani L, Edlund PO, Schuppe-Koistinen I, Jacobsson SP, (2005) Metabolic fingerprinting of rat urine by LC/MS Part 1. Analysis by hydrophilic interaction liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 828: 9-13.
24. Lindon JC, Holmes E, Nicholson JK, (2006) Metabonomics techniques and applications to pharmaceutical research & development. Pharm Res 23: 1075-1088.
25. Beger RD, Sun J, Schnackenberg LK, (2010) Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol Appl Pharmacol 243: 154-166.
26. Bylesjo M, Rantalainen M, Cloarec O, Nicholson J, Holmes E, et al. (2006) OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J Chemom 20: 341-351.
27. Kang J, Choi MY, Kang S, Kwon HN, Wen H, et al. (2008) Application of a 1H nuclear magnetic resonance (NMR) metabolomics approach combined with orthogonal projections to latent structure-discriminant analysis as an efficient tool for discriminating between Korean and Chinese herbal medicines. J Agric Food Chem 56: 11589-11595.
28. Kand'ar R, Zakova P, Muzakova V, (2006) Monitoring of antioxidant properties of uric acid in humans for a consideration measuring of levels of allantoin in plasma by liquid chromatography. Clin Chim Acta 365: 249-256.
29. Weljie AM, Dowlatabadi R, Miller BJ, Vogel HJ, Jirik FR, (2007) An inflammatory arthritis-associated metabolite biomarker pattern revealed by 1H NMR spectroscopy. J Proteome Res 6: 3456-3464.
30. Kumar BS, Lee YJ, Yi HJ, Chung BC, Jung BH, (2010) Discovery of safety biomarkers for atorvastatin in rat urine using mass spectrometry based metabolomics combined with global and targeted approach. Anal Chim Acta 661: 47-59.
31. Krishnan N, Becker DF, (2006) Oxygen reactivity of PutA from Helicobacter species and proline-linked oxidative stress. J Bacteriol 188: 1227-1235.
32. Kolker S, Okun JG, Horster F, Assmann B, Ahlemeyer B, et al. (2001) 3-Ureidopropionate contributes to the neuropathology of 3-ureidopropionase deficiency and severe propionic aciduria: a hypothesis. J Neurosci Res 66: 666-673.
33. Frei B, Kim MC, Ames BN, (1990) Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc Natl Acad Sci U S A 87: 4879-4883.
34. Stocker R, Bowry VW, Frei B, (1991) Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc Natl Acad Sci U S A 88: 1646-1650.
35. Tavintharan S, Ong CN, Jeyaseelan K, Sivakumar M, Lim SC, et al. (2007) Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: a possible role in statin-induced hepatotoxicity? Toxicol Appl Pharmacol 223: 173-179.
36. Kettawan A, Takahashi T, Kongkachuichai R, Charoenkiatkul S, Kishi T, et al. (2007) Protective effects of coenzyme q(10) on decreased oxidative stress resistance induced by simvastatin. J Clin Biochem Nutr 40: 194-202.
37. Kang J, Lee S, Kang S, Kwon HN, Park JH, et al. (2008) NMR-based metabolomics approach for the differentiation of ginseng (Panax ginseng) roots from different origins. Arch Pharm Res 31: 330-336.
38. Wen H, Kang S, Song Y, Song Y, Sung SH, et al. (2010) Differentiation of cultivation sources of Ganoderma lucidum by NMR-based metabolomics approach. Phytochem Anal 21: 73-79.